ImmunityBio Q3 Revenue Up 53% to $48.7M; $1.0B Nine-Month Loss Is Mostly Non-Cash
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, with $334.3 million in cash and securities. The $1.0 billion nine-month net loss was driven mainly by a $749.7 million non-cash fair value charge, not operations.
Key Events · Earnings and Guidance · IBRX
-
Q3 Revenue Grows 53% to $48.7M
Net product revenue reached $48.7 million in Q3 2026 versus $31.8 million a year earlier, and $143.6 million for the first nine months, up 92% from $74.7 million.
-
$1.0B Loss Is Mostly Non-Cash
The nine-month net loss of $1.0 billion includes a $749.7 million non-cash change in fair value of the related-party convertible note and warrant/derivative liabilities; adjusted net loss was $265.2 million.
-
$334.3M Cash Funds BCG-Naïve sBLA
Cash, cash equivalents and marketable securities totaled $334.3 million at September 30, 2026, with the BCG-naïve NMIBC sBLA submission targeted for Q4 2026.
-
Balance Sheet Still Levered
Total liabilities of $1.75 billion, including an $834.9 million related-party convertible note at fair value and a $426.3 million revenue interest liability, leave a $1.15 billion stockholders' deficit.
Analysis · IBRX · Life Sciences
Revenue is compounding fast — $48.7 million in Q3 and $143.6 million for nine months, up 92% — and the $334.3 million cash pile funds the BCG-naïve sBLA submission targeted for Q4 2026. The headline $1.0 billion nine-month loss is almost entirely accounting: a $749.7 million non-cash fair value charge on the related-party convertible note and warrant/derivative liabilities, driven by the rising share price, not by cash leaving the business. The real operating number is the $265.2 million adjusted net loss, and the real balance-sheet fact is a $1.15 billion stockholders' deficit against $1.75 billion of liabilities, which keeps the company dependent on continued financing.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBRX was trading at $8.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.